KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Net Margin (2016 - 2025)

Travere Therapeutics' Net Margin history spans 13 years, with the latest figure at 19.06% for Q4 2025.

  • For Q4 2025, Net Margin rose 1905.0% year-over-year to 19.06%; the TTM value through Dec 2025 reached 6.76%, up 715.0%, while the annual FY2025 figure was 5.04%, 543.0% up from the prior year.
  • Net Margin reached 19.06% in Q4 2025 per TVTX's latest filing, up from 0.01% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 646.92% in Q3 2023 to a low of 113.63% in Q1 2021.
  • Average Net Margin over 5 years is 42.72%, with a median of 9.53% recorded in 2024.
  • Peak YoY movement for Net Margin: skyrocketed 59561bps in 2023, then tumbled -64702bps in 2024.
  • A 5-year view of Net Margin shows it stood at 64.8% in 2021, then skyrocketed by 204bps to 67.53% in 2022, then tumbled by -105bps to 3.5% in 2023, then skyrocketed by 100bps to 0.01% in 2024, then soared by 356206bps to 19.06% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Net Margin are 19.06% (Q4 2025), 0.01% (Q4 2024), and 0.09% (Q3 2024).